One Tech Stock Made Investors Happy Today & One Healthcare Company You Should Follow Hedge Funds Into

Sangamo Biosciences, Inc. (NASDAQ:SGMO) is a company that hedge funds like, even though the sentiment is not as strong as towards other, larger healthcare stocks (for example, Allergan PLC (NYSE:AGN) ranked as the most popular stock overall). During the second quarter, the number of funds bullish on the company went up to 22 from 21, but the aggregate value of their holdings slid to $189.72 million from $246.91 million, amid a 44% drop of the stock. Among these, the largest stake was held by Julian Baker and Felix Baker’s Baker Bros. Advisors, which boosted its position in Sangamo Biosciences, Inc. (NASDAQ:SGMO) by 131% on the quarter to 3.23 million shares reported as of the end of June. Peter Kolchinsky‘s RA Capital Management also reported ownership of some 1.22 million shares, and ‘Call’ options underlying other 6.0 million shares. Other funds with long positions in Sangamo at the end of June, included Phill Gross and Robert Atchinson’s Adage Capital Management and Israel Englander’s Millennium Management.

This shows that hedge funds like the company, and despite the Sangamo Biosciences, Inc. (NASDAQ:SGMO)’s depreciation, they chose to invest more money. Even though their positions in Sangamo amass small portions of their equity portfolios, the company seems like a good bet now and has a chance to surge even higher if it manages to report positive results from the trials.

Disclosure: none